Section
Antitrust
1 story
CVS unit Caremark settles FTC insulin pricing case with up to $8.5 billion in projected consumer savings
The FTC said a settlement with Caremark Rx and Zinc Health Services will separate pharmacy benefit manager fees from drug list prices and cap insulin out-of-pocket costs, resolving the agency's antitrust case against the second of three drug middlemen.